Contributions
Abstract: PB1436
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Diffuse large B cell Lymphoma (DLBCL) is an aggressive histology lymphoma with heterogeneous outcome in the RCHOP immunotherapy era. Although, R-IPI is a useful tool cannot predict accurately outcome for all patients and especially in the real world setting, evidences suggest that sociodemographoc factors are determinants of lymphoma survivorship.
Aims
Our aim was to compare survival in our cohort according to socio-demographic factors.
Methods
In this single center retrospective study we included 253 nodal or extranodal DLBCL patients diagnosed after 2000 and treated with RCHOP. We excluded DLBCL patients with histology of PMBCL n=19, Primary CNS lymphoma n=9, Double hit Lymphoma n=2, Plasmablastic Lymphoma n=1, Lymphoma of the testis n=5 and other than RCHOP first line treatments n=12.
Results
Median age was 67 (16-89 yrs), men to women ratio was 148/92 and among patients in our cohort 186 pts were of Greek origin and 64 were Greek Muslims. Disease characteristics (IPI, Bulky, cell of origin according to Hans Index, stage III-IV) were not different according to ethnic origin except for the presence of ≥ 2 extranodal sites that occurred more frequently in the Greek Muslims cohort ( 33,5% vs 16,3%% for Greeks, p=0,007, chi-square). Overall survival (OS) according to ethnicity/race was statistically indifferent; median OS for Greeks 96 (61.2-130,8) months vs 63 (49-77,7) months for Greek Muslims (Log Rank p=0,084, Figure 1). Percentage of PET/CT complete metabolic response (CMR) after treatment completion was equal 78,8% vs 81% Greeks vs Greek Muslims (p=0,831, table 1).
The Modified Kuppuswamy scale slightly modified was used for SES assessment and according to this model 100 pts in our cohort were considered low SES and 148 high SES. Disease characteristics were similar between low and high SES cohorts except percentage of 1 extranodal sites (low SES 53,5% vs 42,3 for high SES pts, p=0,004) and ≥ 2 extranodal sites (low SES 27,5% vs 16,8% for high SES pts, p=0,004). Low SES patients had more often B-symptoms (62% vs 47,3% for high SES pts, p=0,023). Overall survival (OS) according to SES was statistically indifferent; median OS for low SES 51 (13,7-88,2) months vs 96 (52-140) months for high SES pts ( Log Rank p=0,15, Figure 2). Percentage of PET/CT complete metabolic response (CMR) after treatment completion was equal 87% vs 76,6% for low and high SES respectively (p=0,291).
The Cumulative Illness Rating Scale-Geriatric (CIRS-G) was calculated for all patients and OS according to CIRS-G <3, ≥3 CIRS-G ≤7, and CIRS-G>7 were calculated. Median OS was inferior for DLBCL patients with CIRS-G more or equal to 3; median OS for CIRSG<3 126,5 (103,7-149) months for
CIRSG 3-7 62,4 (52,1-73,6) months and for CIRSG>7 49,9 (35,2-64,7) months ( Log Rank p=0,05, Figure 3).
Conclusion
In conclusion, lymphoma characteristics, CMR achievement and overall survival, except for percentage of patients with extranodal sites that occurred more often in low SES and Greek Muslims DLBCL patients, were not different according to SES and ethnicity/race. The only factor that is adversely related with overall survival is CIRS-G index more or equal to 3.
Keyword(s): Diffuse large B cell lymphoma
Abstract: PB1436
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Diffuse large B cell Lymphoma (DLBCL) is an aggressive histology lymphoma with heterogeneous outcome in the RCHOP immunotherapy era. Although, R-IPI is a useful tool cannot predict accurately outcome for all patients and especially in the real world setting, evidences suggest that sociodemographoc factors are determinants of lymphoma survivorship.
Aims
Our aim was to compare survival in our cohort according to socio-demographic factors.
Methods
In this single center retrospective study we included 253 nodal or extranodal DLBCL patients diagnosed after 2000 and treated with RCHOP. We excluded DLBCL patients with histology of PMBCL n=19, Primary CNS lymphoma n=9, Double hit Lymphoma n=2, Plasmablastic Lymphoma n=1, Lymphoma of the testis n=5 and other than RCHOP first line treatments n=12.
Results
Median age was 67 (16-89 yrs), men to women ratio was 148/92 and among patients in our cohort 186 pts were of Greek origin and 64 were Greek Muslims. Disease characteristics (IPI, Bulky, cell of origin according to Hans Index, stage III-IV) were not different according to ethnic origin except for the presence of ≥ 2 extranodal sites that occurred more frequently in the Greek Muslims cohort ( 33,5% vs 16,3%% for Greeks, p=0,007, chi-square). Overall survival (OS) according to ethnicity/race was statistically indifferent; median OS for Greeks 96 (61.2-130,8) months vs 63 (49-77,7) months for Greek Muslims (Log Rank p=0,084, Figure 1). Percentage of PET/CT complete metabolic response (CMR) after treatment completion was equal 78,8% vs 81% Greeks vs Greek Muslims (p=0,831, table 1).
The Modified Kuppuswamy scale slightly modified was used for SES assessment and according to this model 100 pts in our cohort were considered low SES and 148 high SES. Disease characteristics were similar between low and high SES cohorts except percentage of 1 extranodal sites (low SES 53,5% vs 42,3 for high SES pts, p=0,004) and ≥ 2 extranodal sites (low SES 27,5% vs 16,8% for high SES pts, p=0,004). Low SES patients had more often B-symptoms (62% vs 47,3% for high SES pts, p=0,023). Overall survival (OS) according to SES was statistically indifferent; median OS for low SES 51 (13,7-88,2) months vs 96 (52-140) months for high SES pts ( Log Rank p=0,15, Figure 2). Percentage of PET/CT complete metabolic response (CMR) after treatment completion was equal 87% vs 76,6% for low and high SES respectively (p=0,291).
The Cumulative Illness Rating Scale-Geriatric (CIRS-G) was calculated for all patients and OS according to CIRS-G <3, ≥3 CIRS-G ≤7, and CIRS-G>7 were calculated. Median OS was inferior for DLBCL patients with CIRS-G more or equal to 3; median OS for CIRSG<3 126,5 (103,7-149) months for
CIRSG 3-7 62,4 (52,1-73,6) months and for CIRSG>7 49,9 (35,2-64,7) months ( Log Rank p=0,05, Figure 3).
Conclusion
In conclusion, lymphoma characteristics, CMR achievement and overall survival, except for percentage of patients with extranodal sites that occurred more often in low SES and Greek Muslims DLBCL patients, were not different according to SES and ethnicity/race. The only factor that is adversely related with overall survival is CIRS-G index more or equal to 3.
Keyword(s): Diffuse large B cell lymphoma